Previous Page  7 / 13 Next Page
Information
Show Menu
Previous Page 7 / 13 Next Page
Page Background

Allied Journal of Medical Research

|

Volume 2

Page 47

allied

academies

CANCER THERAPY AND ONCOLOGY

NEUROLOGY AND BRAIN DISORDERS

&

International Conference on

International Conference on

J u n e 2 1 - 2 2 , 2 0 1 8 | O s a k a , J a p a n

Joint Event on

THE STORY OF GLATIRAMER ACETATE (COPAXONE) IN THE

TREATMENT OF MULTIPLE SCLEROSIS - THE POTENTIAL FOR

NEUROPROTECTION BY IMMUNOMODULATORY TREATMENT

Rina Aharoni

The Weizmann Institute of Science, Israel

M

ultiple sclerosis (MS) is currently recognized as complex diseases in which inflammatory autoimmune reactivity in the

central nervous system (CNS) results in demyelination, axonal and neuronal pathology. Treatment strategies thus aim

to reduce the detrimental inflammation and induce neuroprotective repair processes.The synthetic copolymer Copaxone

(glatiramer acetate, GA), an approved drug for the treatment of MS, is the first and so far the only therapeutic agent to have

a copolymer as its active ingredient. Using the animal model of MS - experimental autoimmune encephalomyelitis (EAE),

the mechanism of action of GA was elucidated. These studies indicated that GA treatment generates immunomodulatory

shift from the inflammatory towards the anti-inflammatory pathways, such as Th2-cells that cross the blood brain barrier

(BBB) and secrete

in situ

anti-inflammatory cytokines, as well as T-regulatory cells (Tregs) that suppress the disease.

The consequences of GA treatment on the CNS injury inflicted by the disease were studied using immunohistochemistry,

electron microscopy, and magnetic resonance imaging. These analyses revealed reduced demyelination and neuro-

axonal damages, as well as neuroprotective repair processes such as neurotrophic factors secretion, remyelination and

neurogenesis.These combined findings indicate that immunomodulatory treatment can counteract the neurodegenerative

disease course, supporting linkage between immunomodulation, neuroprotection and therapeutic activity in the CNS.

rina.aharoni@weizmann.ac.il

Allied J Med Res 2018, Volume 2